Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals Inc (NQ: MIRM )

42.00 +0.92 (+2.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Around $4M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed mostly lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
From Travere Therapeutics, Inc.
Via GlobeNewswire
Where Mirum Pharmaceuticals Stands With Analysts
Via Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum’s LIVMARLI® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome
From Mirum Pharmaceuticals
Via Business Wire
The Latest Analyst Ratings for Mirum Pharmaceuticals
Via Benzinga
Analyst Expectations for Mirum Pharmaceuticals's Future
Via Benzinga
Mirum Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Raymond James Maintains Strong Buy Rating for Mirum Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Microsoft To Rally Around 16%? Here Are 10 Other Analyst Forecasts For Tuesday
B of A Securities boosted the price target for Camtek Ltd. (NASDAQ: CAMT) from $30 to $50. B of A Securities analyst Vivek Arya upgraded the stock from Neutral to Buy. Camtek shares rose 1.8% to $44.02... 
Via Benzinga
Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation
Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals... 
Via Benzinga
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
From Travere Therapeutics, Inc.
Via GlobeNewswire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Event-Free Survival Data from Mirum’s LIVMARLI Alagille Syndrome Program Published in Hepatology
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug
Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou... 
Via Talk Markets
Data from Mirum’s LIVMARLI Studies Presented at ESPGHAN Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Hepatology Communications Publishes Data from Mirum’s LIVMARLI in Primary Sclerosing Cholangitis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
From Mirum Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.